- Home
- NMS vs LUNG Comparison
NMS vs LUNG Comparison
Compare NMS & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NMS
- LUNG
- Stock Information
- Founded
- NMS 1993
- LUNG 1995
- Country
- NMS United States
- LUNG United States
- Employees
- NMS N/A
- LUNG N/A
- Industry
- NMS Finance Companies
- LUNG Industrial Specialties
- Sector
- NMS Finance
- LUNG Health Care
- Exchange
- NMS Nasdaq
- LUNG Nasdaq
- Market Cap
- NMS 71.2M
- LUNG 65.6M
- IPO Year
- NMS N/A
- LUNG 2020
- Fundamental
- Price
- NMS $11.75
- LUNG $1.70
- Analyst Decision
- NMS
- LUNG Buy
- Analyst Count
- NMS 0
- LUNG 7
- Target Price
- NMS N/A
- LUNG $7.66
- AVG Volume (30 Days)
- NMS 12.0K
- LUNG 574.6K
- Earning Date
- NMS 01-01-0001
- LUNG 10-29-2025
- Dividend Yield
- NMS 4.11%
- LUNG N/A
- EPS Growth
- NMS N/A
- LUNG N/A
- EPS
- NMS N/A
- LUNG N/A
- Revenue
- NMS N/A
- LUNG $90,549,000.00
- Revenue This Year
- NMS N/A
- LUNG $10.30
- Revenue Next Year
- NMS N/A
- LUNG $14.72
- P/E Ratio
- NMS N/A
- LUNG N/A
- Revenue Growth
- NMS N/A
- LUNG 18.24
- 52 Week Low
- NMS $9.21
- LUNG $1.47
- 52 Week High
- NMS $12.18
- LUNG $9.37
- Technical
- Relative Strength Index (RSI)
- NMS 71.04
- LUNG 43.79
- Support Level
- NMS $11.28
- LUNG $1.60
- Resistance Level
- NMS $11.78
- LUNG $1.80
- Average True Range (ATR)
- NMS 0.09
- LUNG 0.14
- MACD
- NMS 0.05
- LUNG 0.04
- Stochastic Oscillator
- NMS 94.65
- LUNG 36.67
About NMS Nuveen Minnesota Quality Municipal Income Fund
Nuveen Minnesota Quality Municipal Income Fund is a diversified closed-end management investment company. The Fund's primary investment objective is current income exempt from both regular federal income taxes and Minnesota state income taxes and its secondary investment objective is the enhancement of portfolio value.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.